CITIUS PHARMACEUTICALS INC (CTXR)
US17322U2078 - Common Stock
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
/PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split...
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR),...
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR),...
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024.
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Citius Pharma (NASDAQ:CTXR) just reported results for the third quarter of 2024...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the...
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the...
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday,...
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
Penny stock Citius Pharmaceuticals Inc (NASDAQ:CTXR) secures FDA approval on Thursday for Lymphir (denileukin diftitox-cxdl) to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL) in patients after at least one prior systemic therapy. Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product. The company plans to launch Lymphir in the U.S.
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
/PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and Drug Administration (FDA) has...
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second...
Analysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first...
Bloodstream Infections - From Threats to Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second...
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
Biopharma Stocks Transformative Innovation for the Future of Health
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first...
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok®...
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue
Yogi Tea recalls are in effect for some of the company's tea bags over concerns of pesticide residue that may be found in them.
VFS Stock Alert: VinFast Plunges on NHTSA Probe
VinFast Auto stock is down on Tuesday as investors in VFS learn that the company is being investigated over a fatal crash last month.
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Citius Pharmaceuticals stock is up on Tuesday with heavy trading of CTXR shares alongside positive clinical trial results.
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the second quarter of 2024.
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Citius Pharma (NASDAQ:CTXR) just reported results for the second quarter of 202...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
/PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...